SynAct Pharma AB (FRA:8F8)

Market Cap	74.16M -1.4%
Revenue (ttm)	n/a
Net Income	-10.17M
EPS	-0.19
Shares Out	n/a
PE Ratio	n/a
Forward PE	15.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.388
Previous Close	1.380
Day's Range	1.362 - 1.388
52-Week Range	0.968 - 2.320
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ fa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 8
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8F8

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error